Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036634 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients
A Phase 1 study of HIV Infections, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT00036634: Completed Phase 1 study of HIV Infections, sponsored by Gilead Sciences.
NCT00036634 is a Phase 1 study of HIV Infections that has completed, run by Gilead Sciences. The registered enrollment target is 30 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036634, a Phase 1 study of HIV Infections, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).
Primary Outcome
DAVG2 was defined as the time-weighted average between baseline value through the last available value up to week 2 minus the baseline value.
Conditions Studied
Interventions
- DRUG Tenofovir alafenamide
- DRUG Tenofovir DF
Study Locations (3)
California
- Stanford Positive Care Program - Palo Alto
Illinois
- Protocare Trials Chicago Center for Clinical Trials - Chicago
New York
- Rockefeller University Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-03 |
| Est. Completion | 2003-02 |
| Phase | Phase 1 |
What the finished NCT00036634 record still lists
NCT00036634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Tenofovir alafenamide is the first listed.
NCT00036634 reports a single indexed study location in California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00036634 about?
NCT00036634 is a clinical study titled "A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients". This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).
What is the current status of trial NCT00036634?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2002-03. Estimated completion is 2003-02.
What conditions does trial NCT00036634 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00036634?
The interventions under investigation include: Tenofovir alafenamide (DRUG), Tenofovir DF (DRUG).
Who is sponsoring clinical trial NCT00036634?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00036634 being conducted?
This trial has 3 study locations across California, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00036634's enrollment target sits among peer trials
30 426th of 542 higher than 102 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia